

1 Title

2 Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam: a
3 dynamic transmission model

4

5 Author names (first name SURNAME)

6 Olivier LE POLAIN DE WAROUX¹ ; W. John EDMUNDS ¹ ; Kensuke TAKAHASHI² ; Koya
7 ARIYOSHI² ; E. Kim MULHOLLAND^{1,5}; David GOLDBLATT⁶; Yoon Hong CHOI^{3,4} ; Duc-Anh
8 DANG ⁷; Lay Myint YOSHIDA ²; Stefan FLASCHE¹

9

10

11 Affiliations

12 1. Centre for the mathematical modelling of infectious diseases, Department of
13 Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine,
14 London, United Kingdom

15 2. Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

16 3. Immunisation, Hepatitis and Blood Safety Department, Public Health England,
17 London, United Kingdom

18 4. Modelling and Economics Unit, Public Health England, London, United Kingdom

19 5. Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Australia.

20 6. Institute of Child Health, University College London, London, United Kingdom

21 7. National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

22

23

24

25 Corresponding author

26 Olivier LE POLAIN DE WAROUX

27 Address: Department of Infectious Disease Epidemiology, London School of Hygiene and

28 Tropical Medicine Keppel Street, London, WC1E 7HT, UK

29 Phone: +44 (0)7817 372 388 Email: Olivier.lepolain@lshtm.ac.uk

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44 **ABSTRACT**

45 Background

46 Catch-up campaigns (CCs) at the introduction of the pneumococcal conjugate vaccines
47 (PCVs) may accelerate the impact of PCVs. However, limited vaccine supplies may delay
48 vaccine introduction if additional doses are needed for such campaigns. We studied the
49 relative impact of introducing PCV13 with and without catch-up campaign, and the
50 implications of potential introduction delays.

51 Methods

52 We used a dynamic transmission model applied to the population of Nha Trang in Sout
53 central Vietnam. Four strategies were considered: routine vaccination (RV) only, and RV
54 alongside catch-up campaigns among <1y olds (CC1), <2y olds (CC2) and <5y olds (CC5). The
55 model was parameterised with local data on human social contact rates, and was fitted to
56 local carriage data. Post-PCV predictions were based on best estimates of parameters
57 governing post-PCV dynamics, including serotype competition, vaccine efficacy and duration
58 of protection.

59 Results

60 Our model predicts elimination of vaccine-type (VT) carriage across all age groups within 10
61 years of introduction in all scenarios with near-complete replacement by non-VT. Most of
62 the benefit of CCs is predicted to occur within the first 3 years after introduction, with the
63 highest impact in the first year, when IPD incidence is predicted to be 11% (95%CrI 9 – 14%)

64 lower than RV with CC1, 25% (21 – 30 %) lower with CC2 and 38% (32 – 46%) lower with
65 CC5.

66 However, CCs would only prevent more cases of IPD insofar such campaigns do not delay
67 introduction by more than 31 (95%CrI 30 – 32) weeks with CC1, 58 (53 – 63) weeks with CC2
68 and 89 (78 – 101) weeks for CC5.

69 Conclusion

70 CCs are predicted to offer a substantial additional reduction in pneumococcal disease
71 burden over RV alone, if their implementation does not result in much introduction delay.
72 Those findings are important to help guide vaccine introduction in countries that have not
73 yet introduced PCV, particularly in Asia.

74

75 **KEYWORDS**

76 vaccine, pneumococcal, prediction, catch-up, model, transmission

77

78

79

80

81

82

83

84 **Background**

85 Disease due to *Streptococcus pneumoniae* (the pneumococcus) is a leading cause of
86 morbidity and mortality worldwide, disproportionately so in resource-poor settings [1-3].

87

88 Ten- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13), which cover 10
89 and 13 of 94 known serotypes [4], are steadily being introduced into the routine
90 immunisation programmes of many low and lower-middle income countries with the
91 support from Gavi, the Vaccine Alliance [5]. In 2015, 50 out of 73 countries eligible for Gavi
92 support had introduced the vaccine, and eight additional countries have been approved for
93 introduction and are expected to introduce PCV within the next two years [5]. In 2012
94 Pakistan was the first Asian country to routinely introduce PCV, followed by Nepal,
95 Cambodia and Lao PDR [5]. However, PCV has not been introduced in most of Asia, including
96 Vietnam. Globally, the number of infants who had had 3-doses of PCV remains low [6].

97

98 The WHO recommends introducing PCV into childhood immunisation programmes
99 alongside a catch-up campaign (CC) among older children [7], in order to provide direct
100 protection to age groups at particular risk of pneumococcal disease, as well as to accelerate
101 the population impact of the vaccine through herd protection [8].

102

103 However, the magnitude of the additional impact of different CCs over RV remains unclear.
104 Moreover, Gavi has so far not been able to support CCs in eligible countries over concerns
105 that they would increase vaccine introduction delays, given supply constraints [5].

106

107 The aim of our study was to explore the differential impact on carriage and invasive disease
108 of catch-up campaigns targeting various age groups, through a dynamic compartmental
109 model of disease transmission, and also explored the possible impact of delaying vaccine
110 introduction to allow for CCs to be undertaken.

111

112

113

114 **METHODS**

115

116 The model was applied to the population of Nha Trang (~360,000 inhabitants), an urban and
117 semi-rural area in south-central Vietnam.

118

119 **Data**

120

121 *Nasopharyngeal carriage*

122 Two surveys were conducted six month apart among children <5 years randomly drawn
123 from two communes, with 350 children included in January 2008 [9] and another 350
124 children in July 2008 [10].

125

126 Samples were processed and cultured as per WHO recommendations [11]. Serotyping was
127 done by PCR with 29 specific primer pairs which did not differentiate between serotypes 6A
128 and 6B [9]. Given that both antigens are included in PCV13 but that PCV10 does not include
129 6A, we decided to implement our model for PCV13.

130

131 The carriage prevalence of VT and NVT among 5-17 year olds and adults (≥ 18 years) was
132 estimated based on the prevalence and serotype distribution in children < 5 years of age,
133 using a meta-regression model [12].

134

135 *Social mixing patterns*

136 We derived the age-specific contact patterns from a survey conducted in the same area in
137 2010. The survey included a random sample of 2002 individuals drawn from the population
138 census, who completed a diary similar to the one used in the POLYMOD surveys [13], asking
139 about the frequency and characteristics of social encounters over 24 hours. The
140 corresponding mixing matrix was derived as in Melegaro et al. [14]. We parameterised our
141 model based on physical (i.e. skin-to-skin) contacts only, given that *S.pneumoniae* is
142 generally assumed to be transmitted through close interpersonal contact [15].

143

144 **Model structure**

145

146 We built an age-structured deterministic Susceptible-Infected-Susceptible transmission
147 model of carriage acquisition and clearance, in which we modelled VT jointly and separately
148 from NVT, but allowed for co-colonisation, as in previous models [16]. Details about the
149 model structure and model equations can be found in Supplementary File S1.

150

151 The model comprised of three levels of vaccine-induced immunity; (1) no protection, (2)
152 partial protection and (3) full protection. The latter refers to the efficacy and duration of
153 protection conferred after completion of the routine schedule (i.e. 2 infant doses and a
154 booster at 12 months ('2+1' schedule)) or the completion of a catch-up programme in older

155 children (2 doses in <18 months and 1 dose in \geq 18 months). Partial protection was gained
156 from two primary infant doses, or after the first catch-up dose in children aged 12 - 17
157 months. The difference between full and partial protection lied in the magnitude of vaccine
158 efficacy against carriage (VE_c) and in the duration of protection.

159

160 We applied the model to a population of 81 annual age cohorts (0 to 80 years) divided into
161 52 weekly age bands of 100 individuals. In the calculation of the force of infection the
162 population figure was adjusted to represent the actual population, based on census data.

163

164 **Model fitting**

165

166 We fitted the model to pre-vaccination nasopharyngeal prevalence data using a Markov
167 Chain Monte-Carlo (MCMC) algorithm, and estimating the age-specific probability of
168 effective transmission in the absence of PCV. For each posterior sample we simulated up to
169 15 years after vaccine introduction.

170

171 In the calculation of the log-likelihood for carriage, model estimates of VT carriage
172 prevalence included VT carriers and VT-NVT co-colonization given the higher likelihood of
173 our PCR assay to detect VT than NVT colonies in case of multiple colonization [9].

174

175

176

177

178

179 **Model parameters and outputs**

180

181 Table 1 displays the value assigned to the parameters governing transmission and
182 vaccination. Uncertainty around parameters was taken into account by sampling from their
183 posterior distribution in the MCMC process.

184

185 We obtained the vaccine efficacy against carriage conferring full protection (VE_C^F) from a
186 meta-regression model [17]. We estimated the partial efficacy against carriage (VE_C^P) as
187 0.78 (95% CI 0.64 – 0.92) that of VE_C^F through a meta-analysis of the relative risk of VT
188 carriage after full schedules (2+1 or 3+0) compared to partial schedules (2+0), which
189 included four trials [18-21]. Further details are provided in the Supplementary File S2.

190

191 We assumed an exponential decay function for the waning of VE_C^F , as in previous models
192 [16, 22]. We fixed the average duration of protection to 6 years, which best matched the
193 output of a meta-regression model of waning efficacy [17], and analysed the impact of
194 shorter (3 years) and longer (20 years) average protection in sensitivity analyses, based on
195 the uncertainty bounds of the same model [17]. The average duration of protection
196 following partial vaccination was assumed to be 0.78 (95%CI 0.64 – 0.92) that of a complete
197 schedule, as for efficacy. Details are provided in the Supplementary File S2.

198

199 In our base case model we set the vaccination coverage of both routine and catch-up
200 strategies at 90%, in accordance with coverage data from Vietnam [23].

201

202 Carriage estimates were translated into IPD estimates based on the propensity of VT and
203 NVT serotypes to cause illness as a result of carriage, by age, using estimates from Choi et al.
204 [24].

205

206 The impact of PCV on IPD was calculated based on VT and NVT disease propensity, as well as
207 the efficacy against progression to invasive disease as a result of carriage (VE_{inv}). The latter
208 was obtained from a function linking efficacy against IPD (VE_{IPD}) with VE_C and VE_{inv} , where
209 $VE_{IPD} = 1 - (1 - VE_C) * (1 - VE_{inv})$ [25]. VE_{INV} was calculated based on estimates of VE_{IPD} from
210 Lucero et al. [26] and estimates of VE_C derived from [17] (Table1), as detailed in the
211 Supplementary File S2.

212

213 Given limited data on IPD from Nha Trang and Vietnam [27], our main analysis focused on
214 the proportion reduction in IPD, rather than IPD incidence. However, we illustrated how the
215 relative IPD change may translate into disease incidence based on a point estimate in <5y
216 olds of 49 /100,000 as reported for Nha Trang [27]. We did not infer disease impact among
217 ≥ 5 year olds.

218

219 To explore the impact of delayed vaccination, we assumed that for each additional week of
220 delay the incidence of IPD during that time would be at its pre-PCV steady level.

221

222 **Vaccination strategies**

223

224 We explored four different strategies: (i) routine (2+1) vaccination only (RV), and routine
225 vaccination with a catch-up campaign in (ii) <1y olds (CC1), (iii) <2y olds (CC2), and (iv) <5y
226 olds (CC5).

227

228 WHO currently recommends introducing PCV either as a three primary infant dose schedule
229 (3+0) or as two primary doses with a booster at 12 months of age (2+1 schedule), with the
230 choice between schedules guided by setting-specific epidemiological characteristics [7]. We
231 here present the predicted impact of a 2+1 programme, given the relatively low prevalence
232 of carriage in young children in Nha Trang [27].

233

234 **Sensitivity analyses**

235

236 We also ran the model for coverage levels of 50% and 70% in both routine and catch-up
237 programmes. We also explored the impact of duration of protection on our model outputs,
238 based on lower values of 3 years and 20 years, which span across the range of likely values
239 (Figure S3 in File S2).

240

241

242 **RESULTS**

243

244 The carriage prevalence in <5 year olds was 41% (95% CI 38 - 46%) overall, 27% (95%CI 23 -
245 32%) for VT serotypes and 14% (95%CI 11 - 18%) for NVT serotypes. We estimated the
246 carriage prevalence of VT in 5 – 17 year olds and in adults to be 14% (95% CrI 10 – 18%) and

247 3% (95%CrI 0 – 7%) respectively, and that of NVT to be 15% (95%CrI 11 – 19%) and 3%
248 (95%CrI 0 – 7%). Figure 1 shows the model fit to the carriage data.

249

250 **Nasopharyngeal carriage**

251

252 Our model predicts elimination of VT serotypes across all age groups within 10 years of PCV
253 introduction in RV, with near-complete replacement by NVT serotypes, resulting in little or
254 no change in the overall carriage prevalence (Figure 2A&B), particularly in children >5 years
255 and in adults. CCs are predicted to reduce VT carriage more quickly through combined
256 direct and indirect (i.e. herd) effects (Figures 2C and D). In <5 year olds the VT carriage in
257 children is predicted to decrease by >99% within 6 years and 7 months (95% CI 5y2m - 9
258 y6m) in RV, 5 years and 11 months (4y6m– 8 y10m) in CC1, 5 years and 1 month (3y9m –
259 7y10m) in CC2 and 3 yrs (2y2m–4y10m) in CC5. Similar trends are predicted in older
260 children and adults (Figures 2C and 2D).

261

262 **Invasive Pneumococcal Disease (IPD)**

263

264 Our model predicts that the decline of IPD incidence will be proportionally highest among
265 <2 year olds, falling to about 45% (95%CrI 33% - 57%) of its pre-PCV level and would be
266 almost halved (57% (48 – 66%)) in children aged 2 – 4 years respectively (Figure 3A and 3B).

267

268 Most of the benefit of CCs over routine vaccination in children <5 years is predicted to occur
269 within the first three years after PCV introduction, with no noticeable difference at 5 years
270 (Fig 3C). Our model predicts that the relative risk of IPD after CCs compared to RV would be

271 lowest about 1 year after PCV introduction, with differences between strategies reducing
272 thereafter until the new equilibrium is reached. Compared to RV, one year after vaccine
273 introduction the number of cases of IPD is predicted to be 11% (95%CrI 9 – 14%) lower with
274 CC1, 25% (21-30%) lower with CC2 and 38% (32 – 46%) lower with CC5 (Fig 3C).

275

276 The impact of each strategy on the cumulative proportion of cases averted in the first 3
277 years post PCV introduction, compared to no vaccination, is illustrated in Figure 3D.

278

279 Based on an average annual incidence risk of 49/100,000 children <5 years before PCV
280 introduction [27], a routine introduction of PCV would result in a total of 74 cases (95%CrI
281 62 - 86) per 100,000 children <5 years averted over the first five years of programme
282 implementation and catch-up campaigns would lead to the prevention of an additional 13
283 (95%CrI 11 – 16) cases with CC1, 25 (95%CrI 21 – 30) cases with CC2 and 39 (95%CrI 31 – 49)
284 cases with RV5.

285

286

287

288 **Delayed PCV introduction**

289

290 We estimated the relative impact on IPD of catch-up campaigns for increasing delays. Our
291 results suggest that, compared to RV, more IPD cases would be prevented in children <5
292 years insofar as PCV introduction is not delayed by more than 31 weeks (95%CI 30 – 32
293 weeks) for CC1, 58 weeks (53 – 63 weeks) for CC2 and 89 weeks (78 – 101 weeks) for CC5.

294 Vaccination delays would negatively impact <2 year olds more rapidly than 2 – 4 year old
295 (Figure 4).

296

297 **Sensitivity analyses**

298

299 *Vaccination coverage*

300 Our model predicts a lengthening of the time to near-elimination of VT serotypes (and
301 hence, the time to reach the new post-PCV disease equilibrium) as vaccination coverage
302 decreases but a similar differential impact of catch-up campaigns compared to routine
303 vaccination. Full details are provided in the Supplementary File S3.

304

305 *Duration of protection*

306 A duration of protection of 3 years would increase the time to elimination of VT carriage,
307 and thus prevent fewer IPD cases overall, while any average duration of protection longer
308 than 6 years would not change model outcomes. With a duration of 3 years the median
309 prevalence of VT in <5 year olds is predicted to reach near elimination about 2 years later in
310 RV and CC1, 1.5 years later with CC2 and about 1 year later with CC5. Similar differences
311 were predicted for the ≥ 5 year olds (Figure S5 in the Supplementary File S3). The relative
312 impact of one vaccination strategy over another was predicted to be similar than with a
313 duration of 6 years.

314

315 **DISCUSSION**

316

317 We explored the possible impact of introducing PCV13 with and without a catch-up
318 campaign in Vietnam through a dynamic transmission model. Our results feed into current
319 debates about introduction strategies, particularly in South-East Asia where pneumococcal
320 disease burden is high [28], where many countries have not yet introduced PCV [5], and
321 where epidemiological data to guide decision making remain scarce [28, 29]. Although
322 Vietnam is Gavi-eligible and is expected to introduce PCV in the coming years, it has not yet
323 applied [5]. Our results provide estimates about how much catch-up campaigns would
324 decrease disease burden compared to routine vaccine introduction without a campaign, for
325 different scenarios. Our study also shows that, although catch-up campaigns would
326 decrease disease burden more rapidly across age groups, their impact would only be
327 beneficial insofar as the additional supply and operational constraints of their
328 implementation does not delay PCV introduction by more than about 6 months to 2 years,
329 depending on the age cohorts targeted by those campaigns.

330

331 The availability of data on both social mixing patterns – which are central to transmission
332 models [13, 30] – and carriage in the same population allowed for thorough
333 parameterisation of a transmission model.

334

335 However, our study has a number of limitations. In the absence of post-PCV data,
336 predictions were based on the best available estimates of parameters governing vaccine
337 effects that were observed elsewhere [16, 17, 31], which may not fully capture the local
338 characteristics. Given that serotypes differ in their pathogenicity, fitness and transmissibility
339 [32, 33], and that vaccine efficacy and duration of protection differs by serotype [12], our
340 predictions based on homogeneous characteristics for the group of VT and NVT serotypes

341 may overlook local epidemiological characteristics. This uncertainty was nonetheless
342 captured to some extent by sampling from the known uncertainty around those parameters
343 [16]. Moreover, we were not able to assess the impact of PCV on pneumococcal
344 pneumonia, the burden of which is much higher than that of IPD [34], given the lack of
345 robust data and the challenges in the aetiological assessment of clinical pneumonia. Results
346 from ongoing studies in Gavi-eligible countries [35, 36] might help modelling work on the
347 impact of PCV on pneumonia in the future.

348

349 Our predictions are in line with the experience of PCV7 in Europe and North America [37-
350 44], as well with post-PCV trends observed in the few studies from low-income settings
351 [36]. In the region of Kilifi in Kenya, where a catch-up campaign was conducted at PCV
352 introduction, impact studies have shown a two third reduction in VT carriage prevalence
353 across all age groups within two years of PCV10 introduction with a catch-up campaign
354 among children <5 years [43].

355

356 The implementation of PCV in various settings has consistently resulted in little or no
357 change in overall carriage prevalence, due to replacement effects by NVT serotypes
358 colonising the space left vacant by VT in the nasopharynx, but a reduction in severe disease
359 given the lower pathogenicity of the latter, in accordance with our model output. Our
360 predictions were also robust to estimates of duration of protection of vaccination coverage,
361 and thus provide useful estimates of the impact of introducing PCV in a semi-urban
362 Southeast Asian setting.

363

364 While supply issues could also lead to other problems than just delay, such as incomplete
365 schedules once a programme has started, we here assumed that the planning of vaccine
366 introduction would be based on vaccine availability, full roll-out capacity and sustainability
367 at introduction. With supply constraints, and ignoring other supply side, staff and outreach
368 challenges that could potentially delay the implementation of CCs [5], our study can inform
369 whether delaying the introduction of the vaccine to allow for CCs would potentially be
370 beneficial, compared to a routine-only strategy. Moreover, this model also provides a
371 framework that could feed into economic evaluations to further guide decisions about
372 vaccine introduction with and without campaigns.

373

374 The generalisability to other settings of the differential impact of CCs needs to be
375 considered in light of the epidemiological and socio-demographic characteristics of Nha
376 Trang. In particular, the low prevalence of carriage and an ageing population - with only 5%
377 of children under the age of five years – impact on the speed with which herd effects are
378 established. Although similar epidemiological and demographic characteristics are observed
379 in many other South(east) Asian settings [45, 46], the differential impact of CCs and the
380 establishment of herd effects in settings with a younger population and a higher carriage
381 prevalence is likely to differ, and should be addressed with models applied to such settings.

382

383 In conclusion, our study offers insights into the current debate about vaccination strategies
384 when introducing PCV in South-East Asia. Our model suggests that catch-up campaigns have
385 the potential to rapidly decrease carriage and disease across age groups, but are only
386 offering added reduction in disease burden insofar their implementation results in little to
387 no implementation delay.

388

389 **DECLARATIONS**

390• Ethics approval

391 Ethical approval for the field surveys was granted by the institutional review board of the
392 London School of Hygiene and Tropical Medicine and the Ethics Commission of National
393 Institute of Hygiene and Epidemiology, Hanoi and the Nagasaki University.

394•

395• Consent for publication

396•

397• Availability of data and material

398• Other model outputs are available on request. Please contact the corresponding author at
399 olivier.lepolain@gmail.com

400•

401• Competing interests

402 • OLP: none

403 • WJE: WJE's partner works for GSK, who manufacture PCV10.

404 • KT: none

405 • KA: none

406 • EKM: Kim Mulholland has consulted for GSK on PCV vaccine use and nutritional
407 strategies to improve vaccine effectiveness.

408 • DG: has served on ad-hoc advisory boards for Pfizer, GlaxoSmithKline and Merck,
409 and the University College London Institute of Child Health Laboratory receives
410 contract research funding from Pfizer, GlaxoSmithKline and Merck

411 • YHC: none

412 • DDA: none

413 • LMY: none

414 • SF: none

415•

416• Funding

417 For this work Olivier le Polain was supported by a doctoral research fellowship from the AXA
418 Research Fund. The baseline pneumococcal carriage and population data in Nha Trang was
419 obtained from Nha Trang population based cohort study which was supported by Japan
420 Global Research Network for Infectious Diseases (JGRID).

421• Authors' contributions

422

423• Acknowledgements

424 We would like to thank Dr Ana Maria Henao Restrepo, Dr Hope Johnson and Prof Katherine
425 L O'Brien for helpful discussions around the study objectives.

426 We are grateful to the participants of this study and their parents as well as to the staff from
427 Khanh-Hoa Health Service and the medical staff from Khanh Hoa General Hospital for their
428 support. We also thank the staff from the Japan-Vietnam Friendship Laboratory at National

429 Institute of Hygiene and Epidemiology, Hanoi, and Institute of Tropical Medicine, Nagasaki

430 University.

431•

432• Authors' information (optional)

433

434

435 **LIST OF ABBREVIATIONS**

436 CC: Catch-up campaign

437 CC1: CC in <1 year olds

438 CC2: CC in <2 year olds

439 CC5: CC in <5 year olds

440 IPD: Invasive Pneumococcal Disease

441 MCMC: Markov Chain Monte-Carlo

442 NVT: Non vaccine type

443 PCV: pneumococcal conjugate vaccine

444 PCV7: seven-valent PCV

445 PCV10: 10-valent PCV

446 PCV13, 13-valent PCV

447 RV: Routine vaccination

448 VE_C^F : vaccine efficacy against carriage conferring full protection

449 VE_C^P : vaccine efficacy against carriage conferring partial protection

450 VT: Vaccine Type

451

452

453

454

455 **REFERENCES**

- 456 [1] Cohen AL, Hyde TB, Verani J, Watkins M. Integrating pneumonia prevention and
457 treatment interventions with immunization services in resource-poor countries. *Bulletin of*
458 *the World Health Organization*. 2012;90:289-94.
- 459 [2] Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional,
460 and national causes of child mortality in 2008: a systematic analysis. *Lancet*. 2010;375:1969-
461 87.
- 462 [3] Global Action Plan for prevention and control of pneumonia (GAPP). Geneva: World
463 Health Organization; 2008.
- 464 [4] Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, et al.
465 Biochemical, genetic, and serological characterization of two capsule subtypes among
466 *Streptococcus pneumoniae* Serotype 20 strains: discovery of a new pneumococcal serotype.
467 *J Biol Chem*. 2012;287:27885-94.
- 468 [5] Gavi, The Vaccine Alliance, . Advance Market Commitment for Pneumococcal Vaccines.
469 Annual Report 1 April 2014 - 31 March 2015. In: Gavi TVA, editor. 2015.
- 470 [6] Harris JB, Gacic-Dobo M, Eggers R, Brown DW, Sodha SV, Centers for Disease C, et al.
471 Global routine vaccination coverage, 2013. *MMWR Morbidity and mortality weekly report*.
472 2014;63:1055-8.
- 473 [7] Publication WHO. Pneumococcal vaccines WHO position paper - 2012 -
474 recommendations. *Vaccine*. 2012;30:4717-8.
- 475 [8] Whitney CG, Goldblatt D, O'Brien KL. Dosing schedules for pneumococcal conjugate
476 vaccine: considerations for policy makers. *The Pediatric infectious disease journal*. 2014;33
477 Suppl 2:S172-81.
- 478 [9] Vu HT, Yoshida LM, Suzuki M, Nguyen HA, Nguyen CD, Nguyen AT, et al. Association
479 between nasopharyngeal load of *Streptococcus pneumoniae*, viral coinfection, and
480 radiologically confirmed pneumonia in Vietnamese children. *The Pediatric infectious disease*
481 *journal*. 2011;30:11-8.
- 482 [10] Yoshida LM, Nguyen HA, Watanabe K, Le MN, Nguyen AT, Vu HT, et al. Incidence of
483 radiologically-confirmed pneumonia and *Haemophilus influenzae* type b carriage before
484 *Haemophilus influenzae* type b conjugate vaccine introduction in Central Vietnam. *The*
485 *Journal of pediatrics*. 2013;163:S38-43.
- 486 [11] O'Brien KL, Nohynek H, World Health Organization Pneumococcal Vaccine Trials
487 Carriage Working G. Report from a WHO Working Group: standard method for detecting
488 upper respiratory carriage of *Streptococcus pneumoniae*. *The Pediatric infectious disease*
489 *journal*. 2003;22:e1-11.
- 490 [12] Le Polain de Waroux O, Flasche S, Prieto-Merino D, Edmunds WJ. Age-Dependent
491 Prevalence of Nasopharyngeal Carriage of *Streptococcus pneumoniae* before Conjugate
492 Vaccine Introduction: A Prediction Model Based on a Meta-Analysis. *PloS one*.
493 2014;9:e86136.

- 494 [13] Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and
495 mixing patterns relevant to the spread of infectious diseases. *PLoS Med*. 2008;5:e74.
- 496 [14] Melegaro A, Jit M, Gay N, Zagheni E, Edmunds WJ. What types of contacts are
497 important for the spread of infections?: using contact survey data to explore European
498 mixing patterns. *Epidemics*. 2011;3:143-51.
- 499 [15] Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of *Streptococcus pneumoniae*
500 virulence factors in host respiratory colonization and disease. *Nature reviews Microbiology*.
501 2008;6:288-301.
- 502 [16] Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, et al. 7-Valent pneumococcal
503 conjugate vaccination in England and Wales: is it still beneficial despite high levels of
504 serotype replacement? *PLoS One*. 2011;6:e26190.
- 505 [17] Le Polain De Waroux O, Flasche S, Prieto-Merino D, Goldblatt D, Edmunds WJ. The
506 Efficacy and Duration of Protection of Pneumococcal Conjugate Vaccines Against
507 Nasopharyngeal Carriage: A Meta-regression Model. *The Pediatric infectious disease*
508 *journal*. 2015;34:858-64.
- 509 [18] Dagan R, Givon-Lavi N, Porat N, Greenberg D. The effect of an alternative reduced-dose
510 infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate
511 vaccine on pneumococcal carriage: a randomized controlled trial. *Vaccine*. 2012;30:5132-40.
- 512 [19] Russell FM, Carapetis JR, Satzke C, Tikoduadua L, Waqatakirewa L, Chandra R, et al.
513 Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent
514 pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine
515 booster. *Clinical and vaccine immunology : CVI*. 2010;17:1970-6.
- 516 [20] van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, et al. Effect
517 of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on
518 nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. *JAMA :
519 the journal of the American Medical Association*. 2009;302:159-67.
- 520 [21] Ferraro CF, Trotter CL, Nascimento MC, Jusot JF, Omotara BA, Hodgson A, et al.
521 Household crowding, social mixing patterns and respiratory symptoms in seven countries of
522 the African meningitis belt. *PloS one*. 2014;9:e101129.
- 523 [22] Melegaro A, Choi Y, Pebody R, Gay N. Pneumococcal carriage in United Kingdom
524 families: estimating serotype-specific transmission parameters from longitudinal data.
525 *American journal of epidemiology*. 2007;166:228-35.
- 526 [23] Ali M, Canh GD, Clemens JD, Park JK, von Seidlein L, Minh TT, et al. The use of a
527 computerized database to monitor vaccine safety in Viet Nam. *Bulletin of the World Health*
528 *Organization*. 2005;83:604-10.
- 529 [24] Choi YH, Jit M, Flasche S, Gay N, Miller E. Mathematical modelling long-term effects of
530 replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and
531 Wales. *PLoS One*. 2012;7:e39927.
- 532 [25] Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental link
533 between pneumococcal carriage and disease. *Expert review of vaccines*. 2012;11:841-55.
- 534 [26] Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, et al.
535 Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal
536 disease and X-ray defined pneumonia in children less than two years of age. *Cochrane*
537 *database of systematic reviews*. 2009:CD004977.
- 538 [27] Anh DD, Kilgore PE, Slack MP, Nyambat B, Tho le H, Yoshida LM, et al. Surveillance of
539 pneumococcal-associated disease among hospitalized children in Khanh Hoa Province,

- 540 Vietnam. *Clinical infectious diseases : an official publication of the Infectious Diseases*
541 *Society of America*. 2009;48 Suppl 2:S57-64.
- 542 [28] O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of
543 disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global
544 estimates. *Lancet*. 2009;374:893-902.
- 545 [29] Jaiswal N, Singh M, Das RR, Jindal I, Agarwal A, Thumburu KK, et al. Distribution of
546 serotypes, vaccine coverage, and antimicrobial susceptibility pattern of *Streptococcus*
547 *pneumoniae* in children living in SAARC countries: a systematic review. *PloS one*.
548 2014;9:e108617.
- 549 [30] Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-
550 specific transmission parameters for respiratory-spread infectious agents. *AmJEpidemiol*.
551 2006;164:936-44.
- 552 [31] Auranen K, Mehtala J, Tanskanen A, Kaltoft S. Between-strain competition in acquisition
553 and clearance of pneumococcal carriage--epidemiologic evidence from a longitudinal study
554 of day-care children. *AmJEpidemiol*. 2010;171:169-76.
- 555 [32] Lipsitch M, Abdullahi O, D'Amour A, Xie W, Weinberger DM, Tchetgen Tchetgen E, et al.
556 Estimating rates of carriage acquisition and clearance and competitive ability for
557 pneumococcal serotypes in Kenya with a Markov transition model. *Epidemiology*.
558 2012;23:510-9.
- 559 [33] Hogberg L, Geli P, Ringberg H, Melander E, Lipsitch M, Ekdahl K. Age- and serogroup-
560 related differences in observed durations of nasopharyngeal carriage of penicillin-resistant
561 pneumococci. *Journal of clinical microbiology*. 2007;45:948-52.
- 562 [34] Rudan I, El Arifeen S, Bhutta ZA, Black RE, Brooks A, Chan KY, et al. Setting research
563 priorities to reduce global mortality from childhood pneumonia by 2015. *PLoS medicine*.
564 2011;8:e1001099.
- 565 [35] Levine OS, Bhat N, Crawley J, Deloria-Knoll M, DeLuca AN, Driscoll AJ, et al. Pneumonia
566 etiology research for child health. Introduction. *Clinical infectious diseases : an official*
567 *publication of the Infectious Diseases Society of America*. 2012;54 Suppl 2:S87-8.
- 568 [36] Rodgers GL, Klugman KP. Surveillance of the impact of pneumococcal conjugate
569 vaccines in developing countries. *Hum Vaccin Immunother*. 2016;12:417-20.
- 570 [37] Flasche S, van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, et al. Effect of
571 pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in
572 England: a cross-sectional study. *PLoS Med*. 2011;8:e1001017.
- 573 [38] Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, et al.
574 Continued impact of pneumococcal conjugate vaccine on carriage in young children.
575 *Pediatrics*. 2009;124:e1-11.
- 576 [39] Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, et al.
577 Carriage of *Streptococcus pneumoniae* 3 years after start of vaccination program, the
578 Netherlands. *Emerg Infect Dis*. 2011;17:584-91.
- 579 [40] Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, et al. Effect of the 7-valent
580 pneumococcal conjugate vaccine on nasopharyngeal colonization by *Streptococcus*
581 *pneumoniae* in the first 2 years of life. *Clinical infectious diseases : an official publication of*
582 *the Infectious Diseases Society of America*. 2004;39:930-8.
- 583 [41] Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine
584 immunization in two Boston communities: changes in serotypes and antimicrobial
585 susceptibility among *Streptococcus pneumoniae* isolates. *The Pediatric infectious disease*
586 *journal*. 2004;23:1015-22.

- 587 [42] Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL, Hurlburt DA, Parks D, et al. Impact of
588 heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance
589 and colonization in Alaska Natives: progress towards elimination of a health disparity.
590 *Vaccine*. 2005;23:5464-73.
- 591 [43] Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, et al. Indirect
592 effect of conjugate vaccine on adult carriage of *Streptococcus pneumoniae*: an explanation
593 of trends in invasive pneumococcal disease. *J Infect Dis*. 2006;193:1487-94.
- 594 [44] Flasche S, Le Polain de Waroux O, O'Brien KL, Edmunds WJ. The serotype distribution
595 among healthy carriers before vaccination is essential for predicting the impact of
596 pneumococcal conjugate vaccine on invasive disease. *PLoS computational biology*.
597 2015;11:e1004173.
- 598 [45] Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et al. Carriage of
599 *Streptococcus pneumoniae* and Other Respiratory Bacterial Pathogens in Low and Lower-
600 Middle Income Countries: A Systematic Review and Meta-Analysis. *PloS one*.
601 2014;9:e103293.
- 602 [46] UNFPA. UNFPA State of the World Population 2014. 2015.
- 603 [47] Abdullahi O, Karani A, Tigoi CC, Mugo D, Kungu S, Wanjiru E, et al. Rates of acquisition
604 and clearance of pneumococcal serotypes in the nasopharynges of children in Kilifi District,
605 Kenya. *The Journal of infectious diseases*. 2012;206:1020-9.
- 606 [48] Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of
607 pneumococcal carriage in households. *Epidemiol Infect*. 2004;132:433-41.
- 608 [49] Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, et al. Global
609 and regional burden of hospital admissions for severe acute lower respiratory infections in
610 young children in 2010: a systematic analysis. *Lancet*. 2013;381:1380-90.
- 611 [50] Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, et al. Systematic review
612 of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type
613 nasopharyngeal carriage. *The Pediatric infectious disease journal*. 2014;33 Suppl 2:S152-60.
- 614 [51] Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, Nsekpong D, et al. The
615 immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate
616 pneumococcal vaccine immunization schedule. *Vaccine*. 2011;29:2999-3007.

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631 **Tables and Figures**


632 **Table 1:** Parameters used in the model

Parameter	Value	Source*
Competition for carriage acquisition (C_N and C_V)[§]	0.1 (SD 0.01)	[16, 31]
Duration of carriage (δ_i)		
0 – 52 months	47.1 days	[47]
12 – 23 months	39.4 days	[47]
24 – 35 months	31.6 days	[47]
36 – 47 months	21.5 days	[47]
48 – 59 months	21.3 days	[47]
5 – 17 years	17.0 days	[22, 48]
18 years and over	18.0 days	[22, 48]
Vaccine efficacy against carriage		
Full protection (VE_C^F)	62% (95%CrI 52 – 72 %)	[17]
Partial protection (VE_C^P)	0.78 (95%CI 0.64 – 0.92) * VE_C^F	Meta-analysis of [18-21] (Supplementary File S2)
Mean duration of protection against carriage		
In fully protected (D_F)	6.0 years	[17](Supplementary File S2)
In partially protected (D_P)	0.78 (95%CI 0.64 – 0.92) * D_F	Supplementary File S2
Vaccine efficacy against IPD (VE_{IPD})	0.80 (95%CrI 0.61 – 0.90)	[49]

633 [§]Where 0.1 means a force of infection which is 10% that of a situation with no competition

634

635 **Figure 1:** Pre-PCV carriage estimates across age groups for VT (left panel) and NVT (right
636 panel), based on survey (plain vertical lines) and meta-regression model (dotted vertical lines)
637 estimates, and estimates from the corresponding transmission model. **Legend:** Dots
638 and bars correspond to the point and 95% confidence interval for the carriage estimates
639 from the survey data (plain dot and plain lines) and the meta-regression model (cross and
640 dotted lines). The dark red and dark blue plain lines represent the median transmission
641 model estimate for VT and NVT respectively, the shaded areas the 50% credible interval (CrI)
642 around the median and the dotted red and blue lines the 95%CrI
643



644

645

646

647

648

649

650

651


652

653

654

655

656 **Figure 2:** Predicted trends in nasopharyngeal carriage following PCV13 introduction in Nha
657 Trang. **Legend:** A: Predicted trends in VT, NVT and overall carriage in <5 year olds without a
658 catch-up campaign. B: Predicted trends in VT, NVT, and overall carriage in ≥ 5 year olds
659 without a catch-up campaign. C: Predicted prevalence of VT carriage in <5 year olds for each
660 vaccination strategy. D: Predicted prevalence of VT carriage in ≥ 5 year olds for each
661 vaccination strategy. In all four panels: plain line= median, shaded areas= 50% credible
662 intervals and dotted line or whiskers= 95% credible interval
663



664

665


666

667

668

669

670 **Figure 3:** Trends in IPD following PCV introduction in children under five years of age in Nha
671 Trang **Legend:** **A:** Predicted trends the cumulative annual incidence of IPD in children <2
672 years for each vaccination strategy considered, at a 90% vaccination coverage **B:** Predicted
673 trends the cumulative annual incidence of IPD in children aged 2-4 years for each
674 vaccination strategy considered, at a 90% vaccination coverage **C:** Cumulative number of IPD
675 cases saved for each catch up strategy compared to RV, in children <5 years of age. **D:**
676 Overall cumulative number of cases saved for each vaccination strategy, compared to no
677 vaccination, in the first 3 years post PCV introduction. In all four panels: plain line= median,
678 shaded areas= 50% credible intervals and dotted line or whiskers= 95% credible interval
679



680

681

682


683

684

685

686

687 **Figure 4:** Impact of delayed PCV introduction with a catch-up campaign on VT carriage
688 (panel A) and on IPD cases saved (panel B) in children under five years of age. **Legend:** A: <2
689 year olds. B: 2 – 4 year olds C: <5 years olds. The middle plain trend line corresponds to the
690 median estimate (Green=CC1, Blue=CC2, Red=CC5), the dark shaded areas the 50% CrI and
691 the light shaded areas the 95%CrI. The plain horizontal line at 1.00 represents the point
692 below which interventions will be more favourable than a timely RV.



693

*in the 5 years post PCV introduction

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708 **Supplementary File S1: Model structure**

709

710 We built a realistic age-structured deterministic Susceptible-Infected-Susceptible (SIS)
711 transmission model of carriage acquisition and clearance, similar to Choi et al. [16].

712 The model considers all VT serotypes jointly and separately from the group of NVT
713 serotypes, but allows for VT-NVT co-colonization, thus resulting in four compartments of
714 carriage states, namely susceptible, VT carriers, NVT carriers and VT-NVT co-colonized as in
715 Choi et al. [16]. In this model movements from the susceptible to the VT or NVT
716 compartments are determined by age-specific forces of infection for VT (λ_{Vi}) and NVT (λ_{Ni})
717 respectively, and co-colonization is determined by competition parameters (C_N and C_V),
718 which represent the degree with which prior colonization reduces the likelihood of co-
719 colonization. Age-specific recovery rates (r_i) determine the speed with which individuals
720 revert back from the co-colonized to either VT or NVT compartments, and from colonization
721 to susceptible compartments, assuming no natural immunity to carriage.

722

723 The model comprised of three levels of vaccine-induced immunity; (1) no protection, (2)
724 partial protection and (3) full protection (Figure S1). The latter means the efficacy and
725 duration of protection conferred after completion of the infant schedule (i.e. 2 infant doses
726 and a booster at 12 months ('2+1' schedule)) or the completion of a catch-up programme in
727 older children (2 doses in <18 months and 1 dose in ≥ 18 months). Partial protection was
728 gained from two primary infant doses, or after the first catch-up dose in children aged 12 -
729 17 months. The difference between full and partial protection lied in the magnitude of
730 vaccine efficacy against carriage (VE_C) and in the duration of protection.

731

732 We applied the model to a population of 81 annual age cohorts (0 to 80 years) divided into
733 52 weekly age bands of 100 individuals. In the calculation of the force of infection the
734 population figure was adjusted to represent the actual population, based on census data.

735

736 We inferred the impact on IPD based posterior estimates of carriage at each time step,
737 case:carrier ratios for VT and NVT by age group [16], the vaccine efficacy against
738 invasiveness and the vaccination coverage of each weekly age cohort at each time step.


739 Details about parameters of vaccine efficacy are provided in the Supplementary File S2.

740

741 The model equations are provided in Text S1 below.

742

743 **Figure S1:** The three groups of vaccine protection states defined in the model and
744 movement between groups



745

746

747

748 **Text S1:** Model equations

$$\frac{dS_i(t)}{dt} = r_{Vi} * V_i(t) + r_{Ni} * N_i(t) - (\lambda_{Vi}(t) + \lambda_{Ni}(t)) * (\gamma_{i(\text{inf})} + \gamma_{i(\text{catch-up})}) * S_i(t) + \omega_p * Sp_i(t) + \omega_f * Sf_i(t)$$

$$\frac{dV_i(t)}{dt} = \lambda_{Vi}(t) * S_i(t) + r_{Ni} * B_i(t) - (C_N * \lambda_{Ni}(t) + r_{Vi}) * V_i(t) - \gamma_{i(\text{inf})} + \gamma_{i(\text{catch-up})} * V_i(t) + \omega_p * Vp_i(t) + \omega_f * Vf_i(t)$$

$$\frac{dN_i(t)}{dt} = \lambda_{Ni}(t) * S_i(t) + r_{Vi} * B_i(t) - (C_V * \lambda_{Vi}(t) + r_{Ni}) * N_i(t) - \gamma_{i(\text{inf})} + \gamma_{i(\text{catch-up})} * N_i(t) + \omega_p * Np_i(t) + \omega_f * Nf_i(t)$$

$$\frac{dB_i(t)}{dt} = (C_V * \lambda_{Vi}(t) * N_i(t) + C_N * \lambda_{Ni}(t) * V_i(t) - (r_{Ni} + r_{Vi}) * B_i(t) - (\gamma_{i(\text{inf})} + \gamma_{i(\text{catch-up})}) * B_i(t) + \omega_p * Bp_i(t) + \omega_f * Bf_i(t)$$

$$\frac{dSp_i(t)}{dt} = r_{Vi} * Vp_i(t) + r_{Ni} * Np_i(t) - ((1 - VE_{pc}) * \lambda_{Vi}(t) + \lambda_{Ni}(t) + \gamma_{i(\text{booster})} + \omega_p) * Sp_i(t) + \gamma_{i(\text{inf})} * S_i(t)$$

$$\frac{dVp_i(t)}{dt} = (1 - VE_{pc}) * \lambda_{Vi}(t) * Sp_i(t) + r_{Ni} * Bp_i(t) - (C_N * \lambda_{Ni}(t) + \gamma_{i(\text{booster})} + \omega_p) * Vp_i(t) + \gamma_{i(\text{inf})} * V_i(t)$$

$$\frac{dNp_i(t)}{dt} = \lambda_{Ni}(t) * Sp_i(t) + r_{Vi} * Bp_i(t) - (C_V * (1 - VE_{pc}) * \lambda_{Ni}(t) + \gamma_{i(\text{booster})} + \omega_p) * Np_i(t) + \gamma_{i(\text{inf})} * N_i(t)$$

$$\frac{dBp_i(t)}{dt} = (C_V * (1 - VE_{pc}) * \lambda_{Vi}(t) * Np_i(t) + C_N * \lambda_{Ni}(t) * Vp_i(t) - (r_{Ni} + r_{Vi} + \gamma_{i(\text{booster})} + \omega_p) * Bp_i(t) + \gamma_{i(\text{inf})} * B_i(t)$$

$$\frac{dSf_i(t)}{dt} = r_{Vi} * Vf_i(t) + r_{Ni} * Nf_i(t) - ((1 - VE_{fc}) * \lambda_{Vi}(t) + \lambda_{Ni}(t) + \omega_f) * Sf_i(t) + \gamma_{i(\text{booster})} * Sp_i(t) + \gamma_{i(\text{catch-up})} * Sp_i(t)$$

749

$$\frac{dVf_i(t)}{dt} = (1 - VE_{fc}) * \lambda_{Vi}(t) * Sf_i(t) + r_{Ni} * Bf_i(t) - (C_N * \lambda_{Ni}(t) + \omega_f) * Vf_i(t) + \gamma_{i(\text{booster})} * Vp_i(t) + \gamma_{i(\text{catch-up})} * Vp_i(t)$$

$$\frac{dNf_i(t)}{dt} = \lambda_{Ni}(t) * Sf_i(t) + r_{Vi} * Bf_i(t) - (C_V * (1 - VE_{fc}) * \lambda_{Ni}(t) + \omega_f) * Nf_i(t) + \gamma_{i(\text{booster})} * Np_i(t) + \gamma_{i(\text{catch-up})} * Np_i(t)$$

$$\frac{dBf_i(t)}{dt} = (C_V * (1 - VE_{fc}) * \lambda_{Vi}(t) * Nf_i(t) + C_N * \lambda_{Ni}(t) * Vf_i(t) - (r_{Ni} + r_{Vi} + \omega_f) * Bf_i(t) + \gamma_{i(\text{booster})} * Bp_i(t) + \gamma_{i(\text{catch-up})} * Bp_i(t)$$

750

751 i represent the weekly age groups. γ is the vaccination coverage for infant doses (inf), the
 752 booster dose (boost) and the catch-up dose (catch-up). VE_{fc} and VE_{pc} is the vaccine efficacy
 753 against carriage acquisition after full and partial vaccination respectively. ω_p and ω_f
 754 represent the rate of waning immunity after partial and full vaccination.

755

756

757

758

759

760 **Supplementary File S2: Vaccine efficacy and duration of protection**

761

762 **Vaccine efficacy against carriage**

763

764 *Full vaccination*

765 We obtained the vaccine efficacy against carriage after full protection (VE_C^F) and its
766 uncertainty from a Bayesian meta-regression model based on estimates from 22
767 intervention studies. The details have been published elsewhere [17]. The model of vaccine
768 efficacy was run for as many iterations as in our transmission model, so that we could
769 sample one estimate of VE_C^F at each iteration of the post-vaccination simulations.

770

771 *Partial vaccination*

772 A systematic review of the impact of pneumococcal conjugate vaccines on carriage [50]
773 provided information on intervention studies with 2 primary-dose arms where compared
774 with either 2+1 schedules or 3+0 schedules.

775

776 We included individual randomized controlled trials providing nasopharyngeal carriage
777 estimates within 3 – 20 months after a 2-dose infant schedule (2+0 arm) and after a
778 complete schedule (either 3+0 or 2+1 arm). We excluded studies providing carriage
779 estimates within 3 months after vaccination to account for the delay in producing an
780 immune response, and time to carriage clearance under the assumption that existing
781 carriage at the time of vaccination is not affected by PCV [17].

782

783 We extracted data on the number of carriers of VT and total number of individuals swabbed
 784 in each study arm before and after vaccination. We then computed the relative risk of VT
 785 carriage among fully vaccinated compared to partially vaccinated children. The pooled
 786 estimates were obtained through a random effects meta-regression model.

787

788 We pooled estimates from four studies, including trials in Fiji [19], Israel[18], The Gambia
 789 [51] and The Netherlands [20], providing together eight different survey points, into a
 790 simple random effects meta-analysis, not taking into account within-study dependence
 791 given the limited number of data points per study. The details of the studies are provided
 792 in Table S1 below.

793

794 **Table S1:** Studies included in the meta-analysis

Study	Country	Schedule	Age (months)	Time since last dose (months)	Carriers /total	Relative Risk (95%I)
Dagan (2012)[18]*	Israel	3+0	9.5m	3.5m	58/327	0.83 (0.57 – 1.20)
Dagan (2012)[18]*	Israel	2+0	9.5m	3.5m	36/169	ref
Ota (2011)[51]	Gambia	3+0	11m	7m	20/200	0.59 (0.36 – 1.00)
Ota (2011)[51]	Gambia	2+0	11m	8m	33/198	ref
Ota (2011)[51]	Gambia	3+0	15m	11m	24/193	0.80 (0.49 – 1.32)
Ota (2011)[51]	Gambia	2+0	15m	12m	30/196	ref
Russell (2010)[19]	Fiji	3+0	6m	3m	13/127	0.95 (0.47 – 1.89)
Russell (2010)[19]	Fiji	2+0	6m	3m	16/148	ref
Russell (2010)[19]	Fiji	3+0	9m	6m	4/122	0.32 (0.11 – 0.93)
Russell (2010)[19]	Fiji	2+0	9m	6m	15/146	ref
Russell (2010)[19]	Fiji	3+0	12m	9m	8/114	1.25 (0.49 – 3.23)
Russell (2010)[19]	Fiji	2+0	12m	9m	9/143	ref
van Gils (2009)[20]	Netherlands	2+1	18m	7m	51/329	0.64 (0.47 – 0.88)
van Gils (2009)[20]	Netherlands	2+0	18m	14m	79/327	ref
van Gils (2009)[20]	Netherlands	2+1	24m	13m	47/333	0.96 (0.66 -1.39)
van Gils (2009)[20]	Netherlands	2+0	24m	20m	49/332	ref

795 *In this study pooled results were provided for samples taken at 7 months and 12 months of age,
 796 and we therefore considered the age and time since the last dose as the average between the two


797 The pooled relative risk of carriage among children with a full schedule was 78% (95%CI 64
 798 – 92%) that of a partial schedule (Figure S2), with no evidence of heterogeneity ($I^2=3\%$).

799

800 At each iteration of the MCMC, we sampled a value from the relative risk 78% (95%CI 64 –
 801 92%) multiplied by a value of the full vaccine efficacy against carriage acquisition (VE_C^F), to
 802 obtain a measure of the partial efficacy (VE_C^P).

803

804 **Figure S2:** Forest plot of the relative risk of VT carriage of 3 primary doses (2+1 or 3+0), for
 805 four different individual randomized controlled trials (RCTs), at eight different time points
 806 [18-20, 51].



807

808

809

810

811


812 **Duration of protection**

813

814 The duration of protection against carriage acquisition was obtained from le Polain et al
815 [17]. The median estimate of a model of waning efficacy, using an asymptomatic function,
816 closely matched that of an exponential decay with a mean duration of protection of 6 years
817 (Figure S3). Hence, this estimate was taken as the average duration of protection in the
818 main model. For sensitivity analyses, we considered mean durations of 3 years and 20 years
819 as the lower and higher values, as shown in Figure S3.

820

821 **Figure S3:** Duration of protection of PCV against carriage acquisition



822

823 **Legend** : Each circle represents the mean vaccine efficacy estimate for each study included
824 in the analysis – see [17]. The size of the circle is proportional to the study size. The whiskers
825 on either side of each circle represent the 95%CrI around the point estimate. The dark grey

826 area corresponds to the 50% CrI around the main model estimate of vaccine efficacy and its
827 waning (plain black line), and the lighter grey area to the 95% CrI. The blue, red and green
828 dotted lines show the waning with an exponential decay function for a mean duration of
829 protection of 6 years, 3 years and 20 years respectively. Figure adapted from le Polain de
830 Waroux et al. [17], with permission from PIDJ

831

832 In the absence of estimates on the duration of protection of partial vaccination, we assumed
833 that the duration of protection of a partial vaccination was 0.78 (0.64 – 0.92) that of a full
834 vaccination, as for VE_C

835

836 **Vaccine efficacy against Invasive Pneumococcal Disease**

837

838 The vaccine efficacy against invasive pneumococcal disease (VE_{IPD}) can be expressed as a
839 function of the vaccine efficacy against carriage acquisition (VE_C) and the efficacy against
840 progression to disease as a result of carriage, which we here term the vaccine efficacy
841 against invasiveness (VE_{inv}) [25], where $VE_{IPD} = 1 - (1-VE_C)(1-VE_{inv})$.

842

843 Based on estimates from a large systematic review by Lucero et al. [26], we assumed VE_{IPD}
844 to be 80% (95%CI 58 – 90%) and generated a binomial distribution that closely matched
845 those estimates . Hence, we calculated VE_{inv} based on the distribution of VE_{IPD} and that of
846 VE_C and obtained a value of VE_{inv} at each iteration in our MCMC process.


847

848 The mean VE_{inv} was 80% (95%CrI 67 – 90%), the mean VE_C was 62% (95%CrI 52 – 73%) and
849 mean VE_{inv} was 48% (95%CrI 34 – 65%). The distributions are shown in Figure S4 below.

850

851

852 **Figure S4:** Estimates of vaccine efficacy



853

854 **Legend:** density plot of the vaccine efficacy against IPD (left panel), carriage (medium panel)
855 and invasiveness (right panel). The x axis displays the vaccine efficacy.

856

857

858 In the model, was assumed no waning of VE_{inv} , and that VE_{inv} would be conferred after 2
859 primary doses, or any catch-up dose. Although there is evidence that VE_C after partial
860 vaccination differs from that after complete vaccination (see earlier), evidence that the
861 efficacy against progression to invasiveness differs between two and three primary doses is
862 scarce.

863

864 Although it is likely that VE_{inv} wanes over time, we did not consider waning in the main
865 model, given that most of the direct impact of PCV on IPD occurs in the first few years of
866 life, before establishment of the herd immunity effect (see results), and given the lack of
867 estimates of waning of VE_{inv} .

868

869

870

871

872

873 **Supplementary File S3: Sensitivity analysis (coverage and duration of vaccine protection)**

874

875 **Vaccination coverage**

876

877 We explored model outputs with lower vaccination coverage in both cohort and catch-up
878 immunization. Our model predicted a lengthening of the time to near-elimination of VT
879 serotypes (and hence, the time reach the new post-PCV disease equilibrium) as vaccination
880 coverage lowers but a similar differential impact of catch-up campaigns compared to
881 routine vaccination.

882

883 Figure S4 compares predictions of trends in VT carriage for all four strategies and
884 vaccination coverage levels of 90%, 70% and 50%.


885

886 **Duration of protection**

887

888 A duration of protection of 3 years would increase the time to elimination of VT carriage,
889 and thus prevent fewer IPD cases overall, while any average duration of protection longer
890 than 6 years would not change model outcomes. With a duration of 3 years the median
891 prevalence of VT in <5 year olds is predicted to reach near elimination about 2 years later in
892 RV and CC1, 1.5 years later with CC2 and about 1 year later with CC5. Similar differences
893 were predicted for the ≥ 5 year olds (Figure S5). The relative impact of one vaccination
894 strategy over another was predicted to be similar than with a duration of 6 years.

895 **Figure S4:** Impact of vaccination coverage on VT carriage for each strategy considered, and
896 comparing 90%, 70% and 50% homogeneous coverage for each of the four strategies, in
897 children aged 0 – 59 months



898


899 **Legend:** In all four panels: plain horizontal line= median, boxes= 50% credible intervals and
900 whiskers= 95% credible interval, for each of the three levels of vaccination coverage (90%,
901 70%, 50%) and for all four vaccination strategies.

902

903



904


905 **Figure S5:** Comparing model estimates with an average duration of protection of 6 years
906 (blue) and of 3 years (red) for each of the vaccination scenarios considered and by age
907 group










908

909 **Legend:** Percentage reduction in VT carriage in children <5 years (left) and ≥ 5 years old. In
910 blue is are estimates of the main model (average duration of protection of 6 years) and in
911 red are estimates considering a mean duration of protection of 3 years. The plain lines
912 represent the median and the dotted lines the 95% credible interval









Delay in introducing the vaccine

*in the 5 years post PCV introduction